Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | HTR1B | P28222 | 1/20 | 0.52 |
| ▸ | HTR1F | P30939 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28314093 | 0.84 | HTR6 (0.68) | HTR6HTR2A | |
| SCHEMBL1357126 | 0.83 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL9596504 | 0.80 | HTR6 (0.74) | HTR6 | |
| Oxalic Acid SCHEMBL7441099 | 0.80 | HTR6 (0.65) | HTR6HTR2AHTR1DHTR1BHTR7 | |
| SCHEMBL3585571 | 0.79 | HTR6 (1.00) | HTR6 | |
| Oxalic Acid SCHEMBL7433702 | 0.79 | HTR6 (0.90) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL15250049 | 0.79 | HTR6 (1.00) | HTR6 | |
| SCHEMBL3807170 | 0.78 | HTR6 (0.74) | HTR6HTR2A | |
| SCHEMBL28373885 | 0.74 | HTR6 (0.46) | HTR6 | |
| SCHEMBL7561915 | 0.74 | HTR2A (0.66) | HTR6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231160-B1 | TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8138219-B2 | Tryptamine sulfonamides as 5-HT6 antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138219-B2 | Tryptamine sulfonamides as 5-HT6 antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100256106-A1 | TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS | MERCK & CO., INC. (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2231160-A1 | TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009073118-A1 | TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS | MERCK & CO., INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256106-A1 | TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS | HTR6, HTR4, HTR1A | HTR6 1/4885HTR2A 5/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.